Best Healthcare Stocks Ranked by Wall Street Score
Healthcare includes businesses with very different economics—from profitable providers and device makers to development-stage biotechnology companies. This list ranks the healthcare theme with Wall Street Score so users can compare the broader quality and valuation picture.
Current qualifying companies
These are the current highest-ranking companies that meet this page’s defined screen. The list is generated from validated Wall Street Score data and can change as company data and prices refresh.
- #1 Aurinia Pharmaceuticals Inc. (AUPH) — WSS 84/100 · Price $16.1 · Revenue Growth: 27.0%
- #2 Innoviva, Inc. (INVA) — WSS 81/100 · Price $20.62 · Revenue Growth: 17.0%
- #3 Rigel Pharmaceuticals, Inc. (RIGL) — WSS 79/100 · Price $47.24 · Revenue Growth: 58.7%
- #4 Compugen Ltd. (CGEN) — WSS 75/100 · Price $2.41 · Revenue Growth: 47.5%
- #5 Universal Health Services, Inc. (UHS) — WSS 72/100 · Price $175.2 · Revenue Growth: 10.3%
- #6 Theravance Biopharma Inc (TBPH) — WSS 70/100 · Price $17.03 · Revenue Growth: 36.8%
- #7 TransMedics Group, Inc. (TMDX) — WSS 70/100 · Price $88.09 · Revenue Growth: 58.3%
- #8 Zevra Therapeutics, Inc. (ZVRA) — WSS 70/100 · Price $12.15 · Revenue Growth: 96.9%
- #9 Cigna Corporation (CI) — WSS 69/100 · Price $288.51 · Revenue Growth: 18.7%
- #10 Catalyst Pharmaceuticals, Inc. (CPRX) — WSS 69/100 · Price $31.49 · Revenue Growth: 21.6%
- #11 ACADIA Pharmaceuticals Inc. (ACAD) — WSS 68/100 · Price $27.83 · Revenue Growth: 21.5%
- #12 Inspire Medical Systems, Inc. (INSP) — WSS 67/100 · Price $73.55 · Revenue Growth: 20.8%
- #13 Harmony Biosciences Holdings, Inc. (HRMY) — WSS 67/100 · Price $41.52 · Revenue Growth: 22.2%
- #14 Niagen Bioscience Inc (NAGE) — WSS 67/100 · Price $3.04 · Revenue Growth: 24.4%
- #15 ADMA Biologics, Inc. (ADMA) — WSS 66/100 · Price $9.14 · Revenue Growth: 40.6%
- #16 Cronos Group Inc. (CRON) — WSS 66/100 · Price $3.29 · Revenue Growth: 30.8%
- #17 Nutex Health, Inc. (NUTX) — WSS 66/100 · Price $212.07 · Revenue Growth: 88.0%
- #18 Keros Therapeutics, Inc. (KROS) — WSS 66/100 · Price $11.17 · Revenue Growth: 39.2%
- #19 MiMedx Group, Inc. (MDXG) — WSS 66/100 · Price $4.73 · Revenue Growth: 14.1%
- #20 Incyte Corporation (INCY) — WSS 65/100 · Price $121.47 · Revenue Growth: 17.9%
- #21 TG Therapeutics, Inc. (TGTX) — WSS 65/100 · Price $54 · Revenue Growth: 62.4%
- #22 Exelixis, Inc. (EXEL) — WSS 64/100 · Price $56.12 · Revenue Growth: 12.6%
- #23 ANI Pharmaceuticals, Inc. (ANIP) — WSS 64/100 · Price $73.59 · Revenue Growth: 34.7%
- #24 BeOne Medicines AG (ONC) — WSS 64/100 · Price $346.51 · Revenue Growth: 47.4%
- #25 ResMed Inc. (RMD) — WSS 63/100 · Price $218.27 · Revenue Growth: 10.4%
How this research list is built
We select securities classified in the healthcare theme, require a current Wall Street Score, exclude ranking-ineligible securities and sort the remainder by WSS.
How to use the ranking
Open the individual company pages behind the current ranking and compare the headline score with revenue, earnings, free cash flow, cash, debt, valuation, competitive position and company-specific risks. A screening result is a reason to research further, not a forecast.
Questions investors ask
The answers below explain how to interpret this screen and its limitations.
- What types of companies are in healthcare stocks?
Healthcare can include providers, insurers, medical-device companies, pharmaceutical businesses and biotechnology firms, each with different risk profiles. - Why can healthcare rankings change quickly?
Earnings, trial results, regulatory decisions, reimbursement changes and financing events can materially alter a healthcare company's risk and valuation.
Continue your research
Educational research only. Rankings and scores are model outputs based on available data, not personalized investment advice or guarantees of future performance.